Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuland LaboratoriesNSE:NEULANDLAB +7.95%87 Equity-to-Asset is 0.64 as of Mar. 2026, which is 3% above its 10-year median of 0.62. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 87/100 and a GF Value™ of ₹16,238.49 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Neuland Laboratories ranks better than 55.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Neuland Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹18,745 Mil. Neuland Laboratories's Total Assets for the quarter that ended in Mar. 2026 was ₹29,301 Mil.
Therefore, Neuland Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.64.
The historical rank and industry rank for Neuland Laboratories's Equity-to-Asset or its related term are showing as below:
NSE:NEULANDLAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52 Med: 0.62 Max: 0.7
Current: 0.64
During the past 13 years, the highest Equity to Asset Ratio of Neuland Laboratories was 0.70. The lowest was 0.52. And the median was 0.62.
NSE:NEULANDLAB's Equity-to-Asset is ranked better than 55.51% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:NEULANDLAB: 0.64
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Neuland Laboratories Equity-to-Asset Related Terms
Neuland Laboratories Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Neuland Laboratories's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a Equity-to-Asset of 0.64 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Neuland Laboratories and its competitors. This is near median its historical median of 0.62. Over the past decade, Neuland Laboratories' Equity-to-Asset has ranged from 0.52 to 0.70. According to the industry distribution chart, Neuland Laboratories ranks #448 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 44.5%.
Is Neuland Laboratories' Equity-to-Asset too high?
Neuland Laboratories' current Equity-to-Asset of 0.64 is near median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 0.70. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Neuland Laboratories' value of 0.64 is 4.9% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #448 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #448 out of 1007 companies for Equity-to-Asset. This puts Neuland Laboratories in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Neuland Laboratories' value of 0.64 is 4.9% above this benchmark. Historically, Neuland Laboratories' own Equity-to-Asset has ranged from 0.52 to 0.70 over the past decade. While the company's 10-year median is 0.62 vs. the industry median of 0.61, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Equity-to-Asset of 0.64 is 4.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Equity-to-Asset is 0.64, which is near median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹16,238.49, compared to a current price of ₹21,543.00 — trading 32.7% above its estimated fair value. The current Equity-to-Asset is 0.64, which is near median its 10-year median of 0.62 and 4.9% above the Drug Manufacturers industry median of 0.61. Neuland Laboratories' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Equity-to-Asset is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹21,543.00 is trading 32.7% above its estimated GF Value™ of ₹16,238.49.
GuruFocus considers Neuland Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
Equity-to-Asset: 0.64 (near median its 10-year median of 0.62)
GF Value™: ₹16,238.49 vs. price of ₹21,543.00 (32.7% above fair value)
Industry Position: 4.9% above the Drug Manufacturers median (#448 of 1007)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
87GF Score
Get the complete analysis for NSE:NEULANDLAB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
